PE20230111A1 - Inmunoconjugados - Google Patents
InmunoconjugadosInfo
- Publication number
- PE20230111A1 PE20230111A1 PE2022002198A PE2022002198A PE20230111A1 PE 20230111 A1 PE20230111 A1 PE 20230111A1 PE 2022002198 A PE2022002198 A PE 2022002198A PE 2022002198 A PE2022002198 A PE 2022002198A PE 20230111 A1 PE20230111 A1 PE 20230111A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- hvr
- immunoconjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Referida a un polipeptido de interleucina-7 (IL-7) mutante, que comprende al menos una sustitucion de aminoacido en una posicion seleccionada del grupo de E13, V15, V18, D21, Q22, D25, T72, L77, K81, E84, G85, I88, Q136, K139, N143 y M147 de IL-7 humana de acuerdo con SEQ ID NO: 52. Tambien se refiere a un inmunoconjugado, en donde el anticuerpo comprende (a) una region variable de la cadena pesada (VH) que comprende una HVR-H1 que comprende la secuencia de aminoacidos de SEQ ID NO: 1, una HVRH2 que comprende la secuencia de aminoacidos de SEQ ID NO: 2, una HVR-H3 que comprende la secuencia de aminoacidos de SEQ ID NO: 3, y una FR-H3 que comprende la secuencia de aminoacidos de SEQ ID NO: 7 en las posiciones 71-73 de acuerdo con la numeracion Kabat, y (b) una region variable de la cadena liviana (VL) que comprende una HVR-L1 que comprende la secuencia de aminoacidos de SEQ ID NO: 4, una HVRL2 que comprende la secuencia de aminoacidos de SEQ ID NO: 5, y una HVR-L3 que comprende la secuencia de aminoacidos de SEQ ID NO: 6. Ademas, la invencion se refiere a moleculas de polinucleotidos que codifican los polipeptidos de interleucina-7 mutante o los inmunoconjugados, y vectores y celulas huesped que comprenden dichas moleculas de polinucleotidos, asi como a metodos para producir los polipeptidos de interleucina-7 mutante, inmunoconjugados y composiciones farmaceuticas que los comprenden.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20169510 | 2020-04-15 | ||
| PCT/EP2021/059473 WO2021209402A2 (en) | 2020-04-15 | 2021-04-13 | Immunoconjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230111A1 true PE20230111A1 (es) | 2023-01-27 |
Family
ID=70289616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002198A PE20230111A1 (es) | 2020-04-15 | 2021-04-13 | Inmunoconjugados |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230192795A1 (es) |
| EP (1) | EP4135848A2 (es) |
| JP (1) | JP2023521238A (es) |
| KR (1) | KR20230004494A (es) |
| CN (1) | CN115485028A (es) |
| AR (1) | AR121856A1 (es) |
| AU (1) | AU2021256936A1 (es) |
| BR (1) | BR112022020629A2 (es) |
| CA (1) | CA3168460A1 (es) |
| CL (1) | CL2022002751A1 (es) |
| CO (1) | CO2022014884A2 (es) |
| CR (1) | CR20220512A (es) |
| IL (1) | IL294451A (es) |
| MX (1) | MX2022012541A (es) |
| PE (1) | PE20230111A1 (es) |
| TW (1) | TW202200609A (es) |
| WO (1) | WO2021209402A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230250181A1 (en) * | 2021-07-09 | 2023-08-10 | Bright Peak Therapeutics Ag | Modified checkpoint inhibitors and uses thereof |
| AU2022362681A1 (en) * | 2021-10-14 | 2024-04-04 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
| CN118139648A (zh) * | 2021-10-14 | 2024-06-04 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的替代的PD1-IL7v免疫缀合物 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2808353C2 (de) | 1977-04-18 | 1984-01-19 | Hitachi Metals, Ltd., Tokyo | Ohrring |
| DE3676670D1 (de) | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| CA2288600C (en) | 1997-05-02 | 2010-06-01 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR20070085886A (ko) * | 2004-12-09 | 2007-08-27 | 메르크 파텐트 게엠베하 | 감소된 면역원성의 ｉｌ-7 변이체 |
| PL1871805T3 (pl) | 2005-02-07 | 2020-03-31 | Roche Glycart Ag | Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania |
| ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
| JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| SG178443A1 (en) | 2009-08-17 | 2012-04-27 | Roche Glycart Ag | Targeted immunoconjugates |
| AU2010343057B2 (en) | 2009-12-29 | 2017-02-23 | Aptevo Research And Development Llc | Heterodimer binding proteins and uses thereof |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| BR112013011811A2 (pt) | 2010-11-05 | 2023-02-23 | Zymeworks Inc | Modelo de anticorpo heterodimérico estável com mutações no domínio fc |
| CA2820956C (en) * | 2010-12-10 | 2016-05-03 | University Of Central Florida Research Foundation, Inc. | Methods and compositions comprising il-7 receptor ligands |
| HUE029139T2 (hu) | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EP3590965A1 (en) | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| ES2676031T3 (es) | 2012-02-15 | 2018-07-16 | F. Hoffmann-La Roche Ag | Cromatografía de afinidad basada en el receptor Fc |
| KR102382304B1 (ko) | 2012-04-20 | 2022-04-04 | 메뤼스 엔.페. | Ig-유사 분자의 제조방법 및 제조수단 |
| SI3356411T1 (sl) * | 2015-10-02 | 2021-09-30 | F. Hoffmann-La Roche Ag | Bispecifična protitelesa, specifična za PD1 in TIM3 |
| PE20181092A1 (es) | 2015-10-02 | 2018-07-09 | Hoffmann La Roche | Anticuerpos anti-pd1 y metodos de uso |
| MX2019006897A (es) * | 2016-12-13 | 2019-08-22 | Astellas Pharma Inc | Anticuerpo anti cd73 humana. |
| WO2018156649A1 (en) * | 2017-02-22 | 2018-08-30 | Flagship Pioneering, Inc. | Compositions of t cell modulator (tcm) molecules and uses thereof |
| SG11202005036RA (en) * | 2018-01-25 | 2020-06-29 | I Mab Biopharma Us Ltd | Anti-pd-l1 antibody and il-7 fusions |
| US20230071889A1 (en) | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| KR20210107058A (ko) * | 2018-12-21 | 2021-08-31 | 오제 이뮈노테라프틱스 | 인간 pd-1에 대항하는 이작용성 분자 |
| JP2022532249A (ja) * | 2019-05-16 | 2022-07-13 | アーチ オンコロジー，インコーポレイテッド | インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法 |
-
2021
- 2021-04-13 BR BR112022020629A patent/BR112022020629A2/pt unknown
- 2021-04-13 MX MX2022012541A patent/MX2022012541A/es unknown
- 2021-04-13 IL IL294451A patent/IL294451A/en unknown
- 2021-04-13 CR CR20220512A patent/CR20220512A/es unknown
- 2021-04-13 PE PE2022002198A patent/PE20230111A1/es unknown
- 2021-04-13 JP JP2022562714A patent/JP2023521238A/ja active Pending
- 2021-04-13 EP EP21717456.4A patent/EP4135848A2/en active Pending
- 2021-04-13 AU AU2021256936A patent/AU2021256936A1/en active Pending
- 2021-04-13 WO PCT/EP2021/059473 patent/WO2021209402A2/en active Application Filing
- 2021-04-13 CA CA3168460A patent/CA3168460A1/en active Pending
- 2021-04-13 US US17/996,338 patent/US20230192795A1/en active Pending
- 2021-04-13 KR KR1020227035960A patent/KR20230004494A/ko unknown
- 2021-04-13 CN CN202180027849.6A patent/CN115485028A/zh active Pending
- 2021-04-14 TW TW110113346A patent/TW202200609A/zh unknown
- 2021-04-15 AR ARP210101004A patent/AR121856A1/es unknown
-
2022
- 2022-10-06 CL CL2022002751A patent/CL2022002751A1/es unknown
- 2022-10-19 CO CONC2022/0014884A patent/CO2022014884A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3168460A1 (en) | 2021-10-21 |
| WO2021209402A2 (en) | 2021-10-21 |
| IL294451A (en) | 2022-09-01 |
| AR121856A1 (es) | 2022-07-20 |
| BR112022020629A2 (pt) | 2022-11-29 |
| CO2022014884A2 (es) | 2022-11-08 |
| CL2022002751A1 (es) | 2023-05-19 |
| MX2022012541A (es) | 2022-11-07 |
| TW202200609A (zh) | 2022-01-01 |
| AU2021256936A1 (en) | 2022-07-21 |
| CN115485028A (zh) | 2022-12-16 |
| KR20230004494A (ko) | 2023-01-06 |
| CR20220512A (es) | 2022-11-07 |
| EP4135848A2 (en) | 2023-02-22 |
| JP2023521238A (ja) | 2023-05-23 |
| WO2021209402A3 (en) | 2021-12-02 |
| US20230192795A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230111A1 (es) | Inmunoconjugados | |
| PE20141562A1 (es) | Anticuerpos anti-htra1 y metodos de uso | |
| BR112021024333A2 (pt) | Composições terapêuticas compreendendo compostos de n,n-dimetiltriptamina deuterado ou parcialmente deuterado | |
| AR126987A2 (es) | Inmunoconjugados | |
| PE20150614A1 (es) | Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina | |
| RU2010148423A (ru) | Гуманизированные антитела против фактора d и их применения | |
| PE20181363A1 (es) | Variantes optimizadas de anticuerpos anti-vegf | |
| JP2016063812A5 (es) | ||
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| CR20190481A (es) | Composiciones de anticuerpo optimizados para el tratamiento de trastornos oculares | |
| JP2019521649A5 (es) | ||
| AR106949A1 (es) | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales | |
| PE20181336A1 (es) | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos | |
| PE20220392A1 (es) | Moleculas de union a claudina-6 y usos de las mismas | |
| PE20191548A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos | |
| BR112015023084A2 (pt) | anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica | |
| JP6666257B2 (ja) | プロアポトーシス活性を有するｇｄ２−ｏ−アセチル化ガングリオシドに対する抗体 | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| EA202290054A1 (ru) | Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3 | |
| MX2021004454A (es) | Anticuerpos anti-sinucleina. | |
| WO2019089753A3 (en) | Cd137 antibodies and pd-1 antagonists and uses thereof | |
| WO2019118512A3 (en) | Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis | |
| PE20211096A1 (es) | Anticuerpos anti-cd33 y metodos para usarlos | |
| WO2018013775A3 (en) | Granulin compositions and uses related thereto |